Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
2(50%)

Phase Distribution

Ph phase_3
1
25%
Ph phase_4
3
75%

Phase Distribution

0

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution4 total trials
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
3(75.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Terminated(2)

Detailed Status

Completed2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (25.0%)
Phase 43 (75.0%)

Trials by Status

completed250%
terminated250%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_3

Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection

NCT04341727
terminatedphase_4

Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19

NCT04362332
completedphase_4

Assessment of Plasmodium Vivax Chloroquine Resistance in Cambodia:

NCT02118090
completedphase_4

CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi

NCT00125489

Clinical Trials (4)

Showing 4 of 4 trials
NCT04341727Phase 3

Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection

Terminated
NCT04362332Phase 4

Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19

Terminated
NCT02118090Phase 4

Assessment of Plasmodium Vivax Chloroquine Resistance in Cambodia:

Completed
NCT00125489Phase 4

CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4